Harnessing tumor-associated exosomal aminopeptidase N as a dual-function tool for monitoring and tackling chemoresistance in gastric cancer.

Authors

Wangyu Cai, Zheru Ma, Wen Xie, Ende Lin, Shengyuan Zheng, Lingyun Lin, Yuanyuan Xie, Zinan Dong, Peiyu Lv, Jia Cheng, Li Yang, Xiaoteng Fu, Fuxing Zhang, Zengpeng Li, Lin Wang

Published in

Cell communication and signaling : CCS. Jul 15, 2026. Epub Jul 15, 2026.

Abstract

Chemoresistance remains a major obstacle to effective treatment in gastric cancer (GC), with a notable scarcity of clinically applicable biomarkers and therapeutic targets. In this study, we employed an integrated proteomic approach analyzing paired serum samples from GC patients at disease control and progressive disease stages during chemotherapy, exosomes from chemoresistant and chemosensitive GC cells, and corresponding whole-cell proteomes to identify tumor-associated exosomal drivers of chemoresistance. Cross-dataset integration identified aminopeptidase N (APN/CD13) as selectively enriched under chemoresistant conditions. Functional validation demonstrated that APN depletion via shRNA or CRISPR restored cisplatin sensitivity in refractory cells, whereas APN overexpression conferred chemoprotection. A neutralizing anti-APN monoclonal antibody resensitized resistant cells and showed superior efficacy compared with the broad-spectrum peptidase inhibitor bestatin in vivo. Mechanistically, APN sustained a ferroptosis-suppressive state: its inhibition increased ROS and lipid peroxidation, shifted transcriptomic profiles toward pro-ferroptotic pathways, and downregulated the lipid peroxide detoxifier AKR1C2, which correlated with poor prognosis and APN expression in the TCGA-STAD cohort. Exosomal transfer assays confirmed that APN-enriched vesicles disseminated chemoresistance and ferroptosis evasion to sensitive cells, accelerating tumor progression during chemotherapy, whereas APN-deficient exosomes lacked this capacity. Clinically, serum exosomal APN levels robustly distinguished progressive disease from disease control in a cohort of 105 patients (AUC = 0.85; optimal cutoff 0.936 ng/mL). Collectively, these findings position exosomal APN as a dual-function tool, serving both as a dynamic liquid biopsy biomarker and an antibody-targetable node for monitoring and overcoming chemoresistance in gastric cancer.

PMID:
42458480
Bibliographic data and abstract were imported from PubMed on 16 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.